Vertex has been trying to diversify beyond its core business of cystic fibrosis treatments. A key part of has been its new non-opioid pain drug, Journavx, which got US regulatory clearance in January. It was the first new type of painkiller to reach the US market in more than two decades.
Shares of Vertex fell as much as 18% on Tuesday, marking their biggest ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.